Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Benvenga S, Bartolone L, Squadrito S, Lo Giudice F, Trimarchi F
Glycaemic efficacy Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA 1c (MD [95% CI]: 21.61 mmol/mol [23.26 to 19.97] [1.96% (2.11 to 1.82)]), followed by tirzepatide 10 mg (20.19 mmol/mol [21.89 to 18.48] [1.84% (1.99 to 1.69)]), semaglutide 2.0 mg (17.74 mmol/mol [22.03 to 13.45] [1.59% (1.95 to 1.22)]), tirzepatide 5 mg (17.60 mmol/mol [19.36 to 15.84] [1.60% (1.75 to 1.44)]), semaglutide 1.0 mg (15.25 mmol/mol [16.73 to 13.77] [1.39% (1.52 to 1.26)]) and semaglutide 0.5 mg (12.00 mmol/mol [13.74 to 10.26] [1.09% (1.24 to 0.94)]) (Fig
Acknowledgements This work was supported by grants from the NIH (NIAAAR01 AA017442, Z.S.), the Natural Science Foundation of China (81470845, Z.S
For migration and wound closure studies, scratch assays with dermal fibroblasts or keratinocytes are well-established
References Ferrer-Lorente R, Cabot C, Fernndez-Lpez JA, Alemany M
